Aristotle University Of Thessaloniki (AUTH)
Συγκριτική αξιολόγηση δεικτών καρκίνου, οστικού μεταβολισμού και απόπτωσης στην εκτίμηση της θεραπευτικής προσέγγισης, σε ασθενείς με καρκίνο του μαστού και οστικές μεταστάσεις
Abstract
dc:descriptionThe aim of this prospective study has been to evaluate the relative usefulness of a panel of markers for the early evaluation of treatment efficacy in patients with breast cancer (BC) and bone metastases (BM). This panel comprised 32 serum markers: 5 tumor markers, 14 markers associated with bone metabolism (bone formation, bone resorption, osteoclastogenesis) and 13 markers involved in cell apoptosis, tissue invasion and other molecular processes. A total of 424 women participated in the study and they were divided into the following 4 groups: 1) Group A: 153 BC patients (36.08%) with clinical and radiological evidence of bone metastases. 2) Group B: 77 BC patients (18.16%) diagnosed at initial levels without skeletal complications. 3) Group C: 72 patients (16.98%) suffering from benign breast diseases under follow-up. 4) Group D: 122 healthy controls (28.77% of total). The level of the markers was determined in the serum of all participants at patients’ enrollment in the study, one month after the beginning of treatment and 6-8 months later. Levels of OPG, RANKL, CA 27.29, TRAP-5b, BAP, and OPN were determined by a sandwich enzyme-linked immunosorbent assay (ELISA), while CEA, CA 15-3, TPA, CYFRA 21-1, ICTP, PICP, PINP, PIIINP, PTHrP, IGF-1, S100, CT, and OC were assayed with radiometric (RIA, IRMA) methods. For Group A patients we created a conventional "scan score" based on the number of BM in bone scintigraphy (S1: 1-2 BM, S2: 3-6 BM, S3:> 6 BM). Initial scan score S1 was observed in 81 (52.94%) patients, while S2 was observed in 49 (32.03%) patients and S3 in the remaining 23 (15.03%) patients of group A. These patients underwent a thorough clinical and imaging evaluation 6-8 months later. Basic demographic characteristics and the level of markers in the serum were compared with Student’s t test for unpaired observations. Due to the large number of interdependent variables, we proceeded on the technique of factor analysis which has advantages over the technique of multiple regression, because it overcomes the problem of multicollinearity. In the present study, a set of biomarkers comprising TRAP, IGF-1, MMP2, OPG/RANKL and CA 27.29 has been shown to be the most sensitive approach to detect the presence of BM in BC patients, followed by another set of biomarkers consisting of ICTP, CA 15-3, Dickkopf-1 and PINP. Regarding the efficacy of the markers to reflect the extent and severity of skeletal involvement, TNFa, p53, TRAP, IGF1 and OPG/RANKL ratio exhibited the best performance. As far as their predictive strength is concerned, TNFa, p53, IL-6, ICTP, TRAP and CA 15-3 had significantly lower levels in all measurements in patients with remission or stabilization of the disease. After collating the information resulting from ours and relevant studies, we conclude that on the base of the well-established criteria for the low-up of BC+BM patients, there should be built meta-levels including validated markers more accurately refining BC subgroups of similar behavior, so that specialization towards individualization may become reality.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Notopoulos, Athanasios
- Νοτόπουλος, Αθανάσιος
Subjects
dc:subject × 10Rights
dc:rights- Statement dc:rights
-
- BY_NC
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/34960